Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

My 78-year-old father, wobbling to his feet, fidgeted for a tub of Mentos in his fleece pocket and, when the zipper failed to ...

For decades, my dad was consumed by alcoholism and anger. I hoped psychedelic therapy could change him.

Report highlights 104 actions by Alexandre de Moraes involving power concentration, censorship, and third-party impacts in ...

This book introduces the mathematics of stochastic interest rate modeling and the pricing of related derivatives, based on a step-by-step presentation of concepts with a focus on explicit calculations ...